Safety of first-line chemotherapy with metronomic single-agent oral vinorelbine in elderly patients with NSCLC

Manlio Mencoboni, Rosa Angela Filiberti, Paola Taveggia, Lisette Del Corso, Alessandro Del Conte, Maria Grazia Covesnon, Cheti Puccetti, Sara Donati, Laura Auriati, Domenico Amoroso, Andrea Camerini

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in firstline treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points. Patients and Methods: Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%. Results: Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea. Conclusion: Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance.

Original languageEnglish
Pages (from-to)3189-3194
Number of pages6
JournalAnticancer Research
Volume37
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Keywords

  • Elderly
  • Metronomic therapy
  • Non small cell lung cancer
  • Oral therapy
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Safety of first-line chemotherapy with metronomic single-agent oral vinorelbine in elderly patients with NSCLC'. Together they form a unique fingerprint.

Cite this